Clinical research in the European Union is entering a new phase of coordination. The Accelerating Clinical Trials in the EU (ACT EU) initiative, jointly steered by the European Commission, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA), has published a revised workplan covering 2026 and 2027. The update marks a shift from setting up the legal and technical foundations of EU trial regulation toward refining how those systems function in practice.
Why ACT EU Exists
ACT EU was launched in January 2022, timed to coincide with the entry into application of the Clinical Trials Regulation (CTR) and the Clinical Trials Information System (CTIS). Together, these tools were meant to replace a fragmented, country-by-country approval process with a single EU-wide submission and authorisation pathway. The idea was straightforward: a sponsor running a multi-country trial should not have to navigate a dozen separate national procedures with inconsistent timelines and documentation requirements. ACT EU builds on that foundation, translating the ambitions of the European medicines agencies network strategy and the Commission's Pharmaceutical Strategy for Europe into concrete operational priorities.
The stakes are not abstract. The EU's competitiveness as a location for clinical trials affects where pharmaceutical companies choose to test new treatments, how quickly patients gain access to innovative medicines, and how much regulatory friction adds to the cost of drug development. Trial sponsors have long compared regulatory speed across regions, and the EU has faced pressure to demonstrate that its harmonised system delivers real efficiency gains rather than simply adding a new layer of bureaucracy on top of national ones.
What the Revised Workplan Covers
The 2026-2027 workplan, shaped by feedback gathered through ACT EU's multi-stakeholder platform advisory group, organises priorities around three core areas: the day-to-day operation of the Clinical Trials Regulation, maximising the broader impact of clinical trials, and preparedness for running trials during public health emergencies. Analytics, training and communication remain ongoing threads that support all three.
What distinguishes this revision is the addition of newer focus areas that respond to gaps identified since CTIS went live:
- Strengthening meaningful patient involvement throughout the trial lifecycle, from design to reporting of results
- Using clinical trial data to widen access and support more inclusive trial populations
- Ensuring sponsors submit trial results within required timeframes
These additions signal a maturing regulatory approach. Early phases of any major system overhaul tend to focus on getting the infrastructure functioning; later phases turn to questions of equity, transparency and accountability. Timely publication of trial results, for instance, has been a persistent weak point across clinical research globally, with delayed or missing results limiting what regulators, clinicians and future researchers can learn from completed studies.
Implications for Sponsors, Patients and the Broader System
For pharmaceutical companies and contract research organisations, a stable and predictable regulatory framework reduces planning uncertainty and can shorten the path from trial design to patient enrolment. For patients, particularly those with rare or serious conditions, faster and more transparent trial processes can mean earlier access to experimental treatments through structured, monitored pathways rather than informal alternatives.
The emphasis on public health emergency preparedness also reflects lessons drawn from recent global health crises, where the ability to launch and adapt trials quickly proved decisive. Embedding that capability into standard regulatory practice, rather than treating it as an exceptional measure, is a notable shift in institutional thinking.
None of this guarantees faster drug approvals or better outcomes on its own. Regulatory streamlining is one variable among many in a long, costly and scientifically uncertain development process. What the revised ACT EU workplan does offer is a clearer signal of where EU regulators believe the remaining friction lies, and a structured commitment to address it through 2027.